These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22682146)

  • 1. Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry.
    Lee PA; Ross J; Germak JA; Gut R
    Int J Pediatr Endocrinol; 2012 Jun; 2012(1):15. PubMed ID: 22682146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noonan syndrome and Turner syndrome patients respond similarly to 4 years' growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program.
    Lee PA; Ross JL; Pedersen BT; Kotnik P; Germak JA; Christesen HT
    Int J Pediatr Endocrinol; 2015; 2015(1):17. PubMed ID: 26351466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attaining genetic height potential: Analysis of height outcomes from the ANSWER Program in children treated with growth hormone over 5 years.
    Ross JL; Lee PA; Gut R; Germak J
    Growth Horm IGF Res; 2015 Dec; 25(6):286-93. PubMed ID: 26363846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®.
    Lee PA; Germak J; Gut R; Khutoryansky N; Ross J
    Int J Pediatr Endocrinol; 2011 Jul; 2011(1):6. PubMed ID: 21899782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program.
    Miller BS; Ross J; Ostrow V
    Int J Pediatr Endocrinol; 2020; 2020():19. PubMed ID: 33042202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program.
    Backeljauw P; Blair JC; Ferran JM; Kelepouris N; Miller BS; Pietropoli A; Polak M; Sävendahl L; Verlinde F; Rohrer TR
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2653-2665. PubMed ID: 36947589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of age and duration of growth hormone therapy in children with Turner syndrome.
    Ross J; Lee PA; Gut R; Germak J
    Horm Res Paediatr; 2011; 76(6):392-9. PubMed ID: 22156541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing the one- and two-year growth response in children treated with growth hormone: analysis from an observational study.
    Ross J; Lee PA; Gut R; Germak J
    Int J Pediatr Endocrinol; 2010; 2010():494656. PubMed ID: 20981140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study.
    Angulo M; Abuzzahab MJ; Pietropoli A; Ostrow V; Kelepouris N; Tauber M
    Int J Pediatr Endocrinol; 2020 Nov; 2020(1):20. PubMed ID: 33292530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Effectiveness and Safety of Childhood Growth Hormone Treatment in Noonan Syndrome.
    Rohrer TR; Abuzzahab J; Backeljauw P; Birkegård AC; Blair J; Dahlgren J; Júlíusson PB; Ostrow V; Pietropoli A; Polak M; Romano A; Ross J; Sävendahl L; Miller BS
    Horm Res Paediatr; 2020; 93(6):380-395. PubMed ID: 33440388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of two doses of Norditropin
    Ozono K; Ogata T; Horikawa R; Matsubara Y; Ogawa Y; Nishijima K; Yokoya S
    Endocr J; 2018 Feb; 65(2):159-174. PubMed ID: 29109363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis.
    Ross J; Fridman M; Kelepouris N; Murray K; Krone N; Polak M; Rohrer TR; Pietropoli A; Lawrence N; Backeljauw P
    J Endocr Soc; 2023 Mar; 7(5):bvad026. PubMed ID: 36936713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased height standard deviation scores in response to growth hormone therapy to near-adult height in older children with delayed skeletal maturation: results from the ANSWER Program.
    Ross JL; Lee PA; Gut R; Germak J
    Int J Pediatr Endocrinol; 2015; 2015(1):1. PubMed ID: 25904938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status.
    Jorge AAL; Edouard T; Maghnie M; Pietropoli A; Kelepouris N; Romano A; Zenker M; Horikawa R
    Endocr Connect; 2022 Apr; 11(4):. PubMed ID: 35245205
    [TBL] [